Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report

The exact impact of immune checkpoint inhibitors in the course and outcome of COVID-19 in cancer patients is currently unclear. Herein, we present the first description of an elderly melanoma patient who developed COVID-19 pneumonia while under treatment with nivolumab and bempegaldesleukin in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastasopoulou, Amalia, Gkoufa, Aikaterini, Diamantopoulos, Panagiotis, Kazanas, Spyridon, Eliadi, Irene, Samarkos, Michael, Gogas, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295713/
https://www.ncbi.nlm.nih.gov/pubmed/35852114
http://dx.doi.org/10.2217/imt-2021-0331
Descripción
Sumario:The exact impact of immune checkpoint inhibitors in the course and outcome of COVID-19 in cancer patients is currently unclear. Herein, we present the first description of an elderly melanoma patient who developed COVID-19 pneumonia while under treatment with nivolumab and bempegaldesleukin in combination with an investigational PEGylated interleukin (IL-2). We present the clinical characteristics and the laboratory and imaging findings of our patient during the course of COVID-19 pneumonia. Moreover, we discuss the currently available data regarding the mechanism of action of immune checkpoint inhibitors and IL-2 analogs in the treatment of COVID-19. The administration of these agents did not have a negative effect on the outcome of COVID-19 pneumonia in an elderly melanoma patient.

Ejemplares similares